TQB3616 capsules

DRUG3 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

Advanced Lung CarcinomaHR-positive, HER2-negative Advanced Breast CancerHR-positive,HER2-negative in Advanced Breast Cancer

Phase 2

A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.HR-positive, HER2-negative Advanced Breast Cancer

Start: 2021-02-04End: 2023-01-31Target: 120Updated: 2021-03-15

A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Lung Carcinoma

Start: 2021-08-18End: 2023-12-30Target: 126Updated: 2021-09-21

Phase 3

TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

Active, not recruitingNCT05375461

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.HR-positive,HER2-negative in Advanced Breast Cancer

Start: 2022-03-18End: 2025-12-31Target: 287Updated: 2024-09-19

Related Papers

Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial.

2025-12-181 citations

Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor.

2024-04-241 citations